Clozapine orally disintegrating tablets

Not yet clear.

The main ingredient of this product is risperidone, whose chemical name is: 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9,-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one, molecular formula and molecular weight C23H27FN4O2410.49.

This product is in the form of tablets.

Used to treat refractory schizophrenia.

This product is used twice a day or once a day. Common dosage: The first dose is 1 mg (one tablet), twice a day. If tolerated, increase the frequency of 1 mg each time, twice a day on the second and third days. The target dose is reached on the third day: 3 mg each time, twice a day. Some patients may need to increase the dose slowly. 8 mg each time, once a day is also safe and effective. The dosage adjustment time should not be less than one week, increasing or decreasing 1-2 mg each time. The effective dose is 4-16 mg/day, and 4-8 mg/day produces the maximum effect.

1. Common adverse reactions associated with taking this product are: insomnia, anxiety, agitation, headache, and dry mouth. 2. Less common adverse reactions are: drowsiness, fatigue, decreased concentration, constipation, indigestion, nausea, vomiting, abdominal pain, blurred vision, abnormal penile erection, erectile dysfunction, weak ejaculation, sexual apathy, urinary incontinence, rhinitis, rash, and other allergic reactions. 3. It may cause extrapyramidal symptoms, such as: muscle tension, tremor, rigidity, drooling, bradykinesia, akathisia, and acute dystonia. These can be eliminated by reducing the dose or administering anti-Parkinson's syndrome drugs. 4. Occasionally, symptoms of (postural) hypotension, (reflex) tachycardia, or hypertension may occur. 5. Weight gain, edema, and elevated liver enzyme levels may occur. 6. In foreign clinical studies, risperidone tablets were reported to treat elderly patients (average age 85 years old) with dementia-related psychiatric symptoms. The incidence of cerebrovascular adverse events, such as stroke and transient ischemic attacks, including deaths, was significantly higher than that of placebo. 7. Occasionally, water intoxication may occur due to the patient's thirst or dysregulation of antidiuretic hormone secretion (sIADH). 8. It may cause an increase in plasma prolactin concentration, and its related symptoms are: galactorrhea, gynecomastia, menstrual disorders, and amenorrhea. 9. Occasionally, tardive dyskinesia, malignant syndrome, temperature disorders, and epileptic seizures are seen. 10. There are individual reports of mild decreases in neutrophil and/or platelet counts.

Not yet clear.

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: Not yet clear. Precautions for the elderly: Not yet clear.

Drug interactions may occur if used with other drugs. Please consult your doctor or pharmacist for details.

seal.

25mg

24 months

Double-Crane Pharmaceutical(Hainan) Co., Ltd.

• Founded in:

  2004-04-07

• Address:

  No. 2, Yaogu Sanheng Road, Yaogu Industrial Park, Haikou National High-tech Zone

• Tax NO.:

  91460100754396590D

• Registered Funds:

  150 million yuan

• Website:

  Log in to view

• Email:

  Log in to view